Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

argenx SE - American Depositary Shares (NQ: ARGX )

581.21 -10.24 (-1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 349,878
Open 584.37
Bid (Size) 571.43 (1)
Ask (Size) 593.04 (1)
Prev. Close 591.45
Today's Range 574.01 - 584.61
52wk Range 349.86 - 678.21
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
From argenx SE
Via GlobeNewswire
What Analysts Are Saying About argenx Stock
Via Benzinga

Performance

YTD
-6.28%
-6.28%
1 Month
-10.09%
-10.09%
3 Month
-4.07%
-4.07%
6 Month
+8.15%
+8.15%
1 Year
+49.82%
+49.82%

More News

Read More
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Via Investor's Business Daily
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
argenx to Present at TD Cowen 45th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
From argenx SE
Via GlobeNewswire
argenx Highlights 2025 Strategic Priorities
From argenx SE
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
Via Benzinga
Looking Into argenx's Recent Short Interest
Via Benzinga
(ARGX) - Analyzing argenx's Short Interest
Via Benzinga
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
From argenx SE
Via GlobeNewswire
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
From argenx SE
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.